OBJECTIVES: We sought to determine the benefit of @entity3528 ( @entity3528 ) in @entity1 with low-grade serous @entity43 , and whether cytoreduction to no gross @entity66 affects survival. METHODS: A single institution retrospective chart review was conducted in @entity1 with recurrent low-grade @entity189 who underwent @entity3528 between 1995 and 2012. Data including demographics, survival, chemotherapy, disease characteristics at the time of surgery, @entity66 , and operative complications were collected. Overall survival (OS) and progression-free survival (PFS) were calculated. Kaplan-Meier and log-rank tests were used to examine survival outcomes. RESULTS: Forty-one @entity1 met inclusion criteria. The median time between primary @entity5 debulking and @entity3528 was 33.2 months. Of 41 eligible @entity1 who underwent @entity3528 , 32 (78%) had gross @entity66 at the completion of secondary surgery. The median PFS for @entity1 with no gross @entity66 after @entity3528 was 60.3 months, compared to 10.7 months for @entity1 with gross @entity66 (p = 0.008). Median OS from diagnosis for @entity1 with no gross @entity66 after @entity3528 was 167.5 months compared to 88.9 months (p = 0.10). Median OS from the time of @entity3528 for @entity1 with no gross @entity66 was 93.6 months compared to 45.8 months (p = 0.04). Complications occurred in 61% of @entity1 after @entity3528 ; there were no deaths directly attributable to surgery. CONCLUSION: Our results suggest a benefit to @entity3528 in @entity1 with recurrent low-grade @entity189 . Efforts to maximally cytoreduce @entity1 should be made as @entity1 with no gross @entity66 had a better PFS and a trend toward better OS.

The role of secondary cytoreduction in low-grade serous XXXX or peritoneal cancer.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian or peritoneal carcinoma'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity189 :: ('MESH:D002277', 'Disease') :: ['serous carcinoma'] @entity3528 :: ('MESH:D006962', 'Disease') :: ['secondary cytoreductive surgery', 'SCRS']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']
